Key result
Percutaneous aortic valve implantation in high-risk patients with severe aortic stenosis is associated with 1-month mortality rates of 6.4-7.4% for the transfemoral approach and 11.6-18.6% for the transapical approach.
Why the study?
Is percutaneous aortic valve implantation safe in high-risk patients with severe symptomatic aortic stenosis?
Systematic Review (n=2,692)
Is percutaneous aortic valve implantation safe in high-risk patients with severe symptomatic aortic stenosis?
Early observational data on percutaneous aortic valve implantation show substantial short-term mortality, emphasizing the need for randomized controlled trials to establish safety and efficacy before routine clinical adoption.
No takes yet. Share an insight, caveat, or question.
High early mortality with percutaneous aortic valve implantation warrants caution in high-risk patients; leaves open randomized comparison to surgery.
Brabandt et al. (2009) conducted a systematic review in Severe symptomatic aortic stenosis (n=2,692). Percutaneous aortic valve implantation (PAVI) vs. Conventional aortic valve replacement or medical therapy (observational comparison) was evaluated on 1-month mortality. Percutaneous aortic valve implantation in high-risk patients with severe aortic stenosis is associated with 1-month mortality rates of 6.4-7.4% for the transfemoral approach and 11.6-18.6% for the transapical approach.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: